PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer

Preclinical experimentation revealed that established cancers treated with the immunogenic cell death (ICD) inducer oxaliplatin are sensitized to immune checkpoint inhibitors targeting PD-1. In contrast, no such sensitizing effect is observed when cisplatin, a non-immunogenic cell death inducer is u...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Peng, Chen, Jianzhou, Zhao, Liwei, Hollebecque, Antoine, Kepp, Oliver, Zitvogel, Laurence, Kroemer, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235886/
https://www.ncbi.nlm.nih.gov/pubmed/35769948
http://dx.doi.org/10.1080/2162402X.2022.2093518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235886/
https://www.ncbi.nlm.nih.gov/pubmed/35769948
http://dx.doi.org/10.1080/2162402X.2022.2093518

Ejemplares similares